SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
20392977
Source:
http://linkedlifedata.com/resource/pubmed/id/20392977
Search
Subject
(
55
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0022972
,
umls-concept:C0026896
,
umls-concept:C0393022
,
umls-concept:C1524063
pubmed:issue
6
pubmed:dateCreated
2011-5-9
pubmed:abstractText
To assess the treatment effects of rituximab in a population of patients with myasthenia gravis and Lambert-Eaton myasthenic syndrome.
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/2985191R
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...
,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors
,
http://linkedlifedata.com/resource/pubmed/chemical/MUSK protein, human
,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases
,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor Protein-Tyrosine Kinases
,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cholinergic
,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1468-330X
pubmed:author
pubmed-author:DaviesNicholasN
,
pubmed-author:FarrugiaMaria ElenaME
,
pubmed-author:Hilton-JonesDavidD
,
pubmed-author:JungbluthHeinzH
,
pubmed-author:MaddisonPaulP
,
pubmed-author:McConvilleJohnJ
,
pubmed-author:NorwoodFionaF
,
pubmed-author:RobbStephanieS
,
pubmed-author:RoseMichaelM
pubmed:issnType
Electronic
pubmed:volume
82
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
671-3
pubmed:meshHeading
pubmed-meshheading:20392977-Adolescent
,
pubmed-meshheading:20392977-Adult
,
pubmed-meshheading:20392977-Antibodies, Monoclonal, Murine-Derived
,
pubmed-meshheading:20392977-Child
,
pubmed-meshheading:20392977-Child, Preschool
,
pubmed-meshheading:20392977-Female
,
pubmed-meshheading:20392977-Humans
,
pubmed-meshheading:20392977-Immunologic Factors
,
pubmed-meshheading:20392977-Lambert-Eaton Myasthenic Syndrome
,
pubmed-meshheading:20392977-Male
,
pubmed-meshheading:20392977-Middle Aged
,
pubmed-meshheading:20392977-Myasthenia Gravis
,
pubmed-meshheading:20392977-Protein-Tyrosine Kinases
,
pubmed-meshheading:20392977-Receptor Protein-Tyrosine Kinases
,
pubmed-meshheading:20392977-Receptors, Cholinergic
,
pubmed-meshheading:20392977-Retrospective Studies
pubmed:year
2011
pubmed:articleTitle
The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
pubmed:affiliation
Department of Neurology, Queen's Medical Centre, Derby Road, Nottingham NG7 2UH, UK. paul.maddison@nhs.net
pubmed:publicationType
Journal Article